Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 176

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Advances in CRISPR therapeutics

Open access
Chavez, Michael, Chen, Xinyi, Finn, Paul B., Qi, Lei S. · 2023 · Nature Reviews Nephrology

Abstract

The clustered regularly interspaced short palindromic repeats (CRISPR) renaissance was catalysed by the discovery that RNA-guided prokaryotic CRISPR-associated (Cas) proteins can create targeted double-strand breaks in mammalian genomes. This finding led to the development of CRISPR systems that harness natural DNA repair mechanisms to repair deficient genes more easily and precisely than ever before. CRISPR has been used to knock out harmful mutant genes and to fix errors in coding sequences to rescue disease phenotypes in preclinical studies and in several clinical trials. However, most genetic disorders result from combinations of mutations, deletions and duplications in the coding and non-coding regions of the genome and therefore require sophisticated genome engineering strategies beyond simple gene knockout. To overcome this limitation, the toolbox of natural and engineered CRISPR–Cas systems has been dramatically expanded to include diverse tools that function in human cells for precise genome editing and epigenome engineering. The application of CRISPR technology to edit the non-coding genome, modulate gene regulation, make precise genetic changes and target infectious diseases has the potential to lead to curative therapies for many previously untreatable diseases. CRISPR systems are RNA-guided ribonucleoproteins that function as both sequence-specific nucleic acid-targeting proteins and nucleases; these systems are being developed as therapies for simple Mendelian disorders. Novel approaches using newly discovered CRISPR systems and Cas protein engineering have expanded the available genome engineering toolbox, enabling the development of potentially curative therapies for diseases with complex drivers. Targeting and altering the non-coding genome with CRISPR could potentially ameliorate disease by changing the transcription or translation of target genes. The use of CRISPR systems with nuclease-dead Cas proteins fused to transcriptional or epigenetic modulators enables targeted gene regulation without inducing DNA damage or altering the genetic code. CRISPR base editors and prime editors can be used to create precise genome edits such as therapeutic mutations, insertions or deletions that are difficult to achieve using wild-type CRISPR–Cas nucleases. In addition to genome engineering, the CRISPR toolbox could potentially be used to prevent and treat infectious diseases. This Review focuses on the potential applications of CRISPR to treat diseases that cannot be overcome by inducing frameshifts or premature stops in coding genes. The authors discuss Cas protein engineering and CRISPR systems beyond Cas9 that create a toolbox to engineer the human genome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41581-022-00636-2

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 176

Metadata

Authors
Chavez, M., Chen, X., Finn, P. B., & Qi, L. S.
Venue
Nature Reviews Nephrology
Published
2022-10-24
Volume
19
Issue
1
Pages
9-22
ISSN
  • 1745-8323 (ISSN-L)
  • 1759-5061
  • 1759-507X
OpenAlex
W4307386237
Cited by
176
References
32
FWCI
3.03
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advances in CRISPR therapeutics. https://app.cochat.ai/papers/10.1038/s41581-022-00636-2
The paper
Chavez, M., Chen, X., Finn, P. B., & Qi, L. S. (2023). Advances in CRISPR therapeutics. Nature Reviews Nephrology. https://doi.org/10.1038/s41581-022-00636-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.